Abstract

Review Article

Update on the Use of Mesenchymal Stem Cells in the Treatment of Various Infectious Diseases Including COVID-19 Infection

Khalid A Al-Anazi* and Rehab Y Al-Ansari

Published: 05 December, 2023 | Volume 7 - Issue 1 | Pages: 034-042

Mesenchymal Stem Cells (MSCs) have antimicrobial, anti-inflammatory, immunomodulatory, and regenerative potentials. Additionally, utilization of MSCs in the clinical arena has been shown to be safe and well tolerated. Hence, this form of cellular therapy has gained particular attention in the treatment of several infectious disorders and their complications. 
MSCs have been successfully used in the treatment of the following infections and their complications: bacterial infections including complicated sepsis; viral infections including Human Immunodeficiency Virus (HIV), hepatitis B and C viruses, and Coronavirus disease (COVID-19) complicated by acute respiratory distress syndrome; parasitic infections including schistosomiasis, malaria, and Chagas disease; and mycobacterial infections including tuberculosis. The use of MSCs derived from certain sources and Extracellular Vesicles (ECVs) derived from MSCs has improved their efficacy and reduced their side effects. However, the clinical application of MSCs in the treatment of several infectious diseases still faces real challenges that need to be resolved. The current status of MSCs and the controversies related to their utilization in various infections will be thoroughly discussed in this review. 

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001033 Cite this Article Read Full Article PDF

Keywords:

Mesenchymal stem cells; Sepsis; Acute respiratory distress syndrome; Chagas disease; Mycobacterial tuberculosis; COVID-19 infection

References

  1. Shaw TD, Krasnodembskaya AD, Schroeder GN, Zumla A, Maeurer M, O'Kane CM. Mesenchymal Stromal Cells: An Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases. Clin Microbiol Rev. 2021 Dec 15;34(4):e0006421. doi: 10.1128/CMR.00064-21. Epub 2021 Oct 6. PMID: 34612662; PMCID: PMC8510528.
  2. Al-Anazi KA, Al-Anazi WK, Al-Jasser AM. Update on COVID-19 infections and the promising role of mesenchymal stem cell therapies in their management. Electronic Book. Heighten Science Publications Inc (HSPI) Published: June 23, 2020. doi: https://dx.doi.org/10.29328/ebook1002
  3. Al-Anazi KA, Al-Anazi WK, Al-Jasser AM. The rising role of mesenchymal stem cells in the treatment of various infectious complications. In: Update on Mesenchymal and Induced Pluripotent Stem Cells. Book edited by: Khalid Ahmed Al-Anazi. Intech Open. 2020. doi: 10.5772/intechopen. 91475
  4. Yudintceva N, Mikhailova N, Fedorov V, Samochernych K, Vinogradova T, Muraviov A, Shevtsov M. Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice. Bioengineering (Basel). 2022 Nov 8;9(11):662. doi: 10.3390/bioengineering9110662. PMID: 36354573; PMCID: PMC9687734.
  5. Sharma A, Chakraborty A, Jaganathan BG. Review of the potential of mesenchymal stem cells for the treatment of infectious diseases. World J Stem Cells. 2021 Jun 26;13(6):568-593. doi: 10.4252/wjsc.v13.i6.568. PMID: 34249228; PMCID: PMC8246252.
  6. Battah B. Mesenchymal stem cells: Potential role against bacterial infection. J Biosci Med. 2022; 10 (3): 97-113. doi: 10.4236/jbm.2022.103011
  7. Lombardo E, van der Poll T, DelaRosa O, Dalemans W. Mesenchymal stem cells as a therapeutic tool to treat sepsis. World J Stem Cells. 2015 Mar 26;7(2):368-79. doi: 10.4252/wjsc.v7.i2.368. PMID: 25815121; PMCID: PMC4369493.
  8. Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies. Front Immunol. 2017 Mar 30; 8:339. doi: 10.3389/fimmu.2017.00339. PMID: 28424688; PMCID: PMC5371613.
  9. Galderisi U, Peluso G, Di Bernardo G. Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years? Stem Cell Rev Rep. 2022 Jan;18(1):23-36. doi: 10.1007/s12015-021-10231-w. Epub 2021 Aug 16. PMID: 34398443; PMCID: PMC8365566.
  10. Yang G, Fan X, Liu Y, Jie P, Mazhar M, Liu Y, Dechsupa N, Wang L. Immunomodulatory Mechanisms and Therapeutic Potential of Mesenchymal Stem Cells. Stem Cell Rev Rep. 2023 Jul;19(5):1214-1231. doi: 10.1007/s12015-023-10539-9. Epub 2023 Apr 14. PMID: 37058201; PMCID: PMC10103048.
  11. Zhuang WZ, Lin YH, Su LJ, Wu MS, Jeng HY, Chang HC, Huang YH, Ling TY. Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci. 2021 Apr 14;28(1):28. doi: 10.1186/s12929-021-00725-7. PMID: 33849537; PMCID: PMC8043779.
  12. Carp DM, Liang Y. Universal or Personalized Mesenchymal Stem Cell Therapies: Impact of Age, Sex, and Biological Source. Cells. 2022 Jun 30;11(13):2077. doi: 10.3390/cells11132077. PMID: 35805161; PMCID: PMC9265811.
  13. Margiana R, Markov A, Zekiy AO, Hamza MU, Al-Dabbagh KA, Al-Zubaidi SH, Hameed NM, Ahmad I, Sivaraman R, Kzar HH, Al-Gazally ME, Mustafa YF, Siahmansouri H. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther. 2022 Jul 28;13(1):366. doi: 10.1186/s13287-022-03054-0. PMID: 35902958; PMCID: PMC9330677.
  14. Fraile M, Eiro N, Costa LA, Martín A, Vizoso FJ. Aging and Mesenchymal Stem Cells: Basic Concepts, Challenges and Strategies. Biology (Basel). 2022 Nov 18;11(11):1678. doi: 10.3390/biology11111678. PMID: 36421393; PMCID: PMC9687158.
  15. Berebichez-Fridman R, Montero-Olvera PR. Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. Sultan Qaboos Univ Med J. 2018 Aug;18(3):e264-e277. doi: 10.18295/squmj.2018.18.03.002. Epub 2018 Dec 19. PMID: 30607265; PMCID: PMC6307657.
  16. Costela-Ruiz VJ, Melguizo-Rodríguez L, Bellotti C, Illescas-Montes R, Stanco D, Arciola CR, Lucarelli E. Different Sources of Mesenchymal Stem Cells for Tissue Regeneration: A Guide to Identifying the Most Favorable One in Orthopedics and Dentistry Applications. Int J Mol Sci. 2022 Jun 6;23(11):6356. doi: 10.3390/ijms23116356. PMID: 35683035; PMCID: PMC9181542.
  17. Yang CW, Chen RD, Zhu QR, Han SJ, Kuang MJ. Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis. Front Immunol. 2022 Aug 29; 13:923286. doi: 10.3389/fimmu.2022.923286. PMID: 36105796; PMCID: PMC9467457.
  18. Couto PS, Al-Arawe N, Filgueiras IS, Fonseca DLM, Hinterseher I, Catar RA, Chinnadurai R, Bersenev A, Cabral-Marques O, Moll G, Verter F. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery. Front Immunol. 2023 Jun 21; 14:1200180. doi: 10.3389/fimmu.2023.1200180. PMID: 37415976; PMCID: PMC10321603.
  19. Chu M, Wang H, Bian L, Huang J, Wu D, Zhang R, Fei F, Chen Y, Xia J. Nebulization Therapy with Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for COVID-19 Pneumonia. Stem Cell Rev Rep. 2022 Aug;18(6):2152-2163. doi: 10.1007/s12015-022-10398-w. Epub 2022 Jun 4. PMID: 35665467; PMCID: PMC9166932.
  20. Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, Mariana N, Antarianto RD, Liem IK, Kispa T, Mujadid F, Novialdi N, Luviah E, Kurniawati T, Lubis AMT, Rahmatika D. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl Med. 2021 Sep;10(9):1279-1287. doi: 10.1002/sctm.21-0046. Epub 2021 Jun 8. PMID: 34102020; PMCID: PMC8242692.
  21. Johnson V, Webb T, Norman A, Coy J, Kurihara J, Regan D, Dow S. Activated Mesenchymal Stem Cells Interact with Antibiotics and Host Innate Immune Responses to Control Chronic Bacterial Infections. Sci Rep. 2017 Aug 29;7(1):9575. doi: 10.1038/s41598-017-08311-4. PMID: 28851894; PMCID: PMC5575141.
  22. Pezzanite LM, Chow L, Phillips J, Griffenhagen GM, Moore AR, Schaer TP, Engiles JB, Werpy N, Gilbertie J, Schnabel LV, Antczak D, Miller D, Dow S, Goodrich LR. TLR-activated mesenchymal stromal cell therapy and antibiotics to treat multi-drug resistant Staphylococcalseptic arthritis in an equine model. Ann Transl Med. 2022 Nov;10(21):1157. doi: 10.21037/atm-22-1746. PMID: 36467344; PMCID: PMC9708491.
  23. Johnson V, Chow L, Harrison J, Soontararak S, Dow S. Activated Mesenchymal Stromal Cell Therapy for Treatment of Multi-Drug Resistant Bacterial Infections in Dogs. Front Vet Sci. 2022 Jun 23; 9:925701. doi: 10.3389/fvets.2022.925701. PMID: 35812842; PMCID: PMC9260693.
  24. Javaregownda PK, Yoon JW, Jang G. Roles of mesenchymal stem cells (MSCs) in bacterial diseases. J Biomed Res. 2013: 184-194.
  25. Yang H, Xu F, Zheng X, Yang S, Ren Z, Yang J. Human Umbilical Cord Mesenchymal Stem Cells Prevent Bacterial Biofilm Formation. Biomed Res Int. 2022 Mar 3; 2022:1530525. doi: 10.1155/2022/1530525. PMID: 35281594; PMCID: PMC8913149.
  26. Laroye C, Gibot S, Reppel L, Bensoussan D. Concise Review: Mesenchymal Stromal/Stem Cells: A New Treatment for Sepsis and Septic Shock? Stem Cells. 2017 Dec;35(12):2331-2339. doi: 10.1002/stem.2695. Epub 2017 Sep 16. PMID: 28856759.
  27. Cheng Y, Cao X, Qin L. Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy for Sepsis. Front Immunol. 2020 Apr 21; 11:647. doi: 10.3389/fimmu.2020.00647. PMID: 32373121; PMCID: PMC7186296.
  28. Daniel M, Bedoui Y, Vagner D, Raffray L, Ah-Pine F, Doray B, Gasque P. Pathophysiology of Sepsis and Genesis of Septic Shock: The Critical Role of Mesenchymal Stem Cells (MSCs). Int J Mol Sci. 2022 Aug 17;23(16):9274. doi: 10.3390/ijms23169274. PMID: 36012544; PMCID: PMC9409099.
  29. Horák J, Nalos L, Martínková V, Beneš J, Štengl M, Matějovič M. Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley? Stem Cells Int. 2017; 2017:7304121. doi: 10.1155/2017/7304121. Epub 2017 Sep 14. PMID: 29098010; PMCID: PMC5618761.
  30. Matthay MA, Pati S, Lee JW. Concise Review: Mesenchymal Stem (Stromal) Cells: Biology and Preclinical Evidence for Therapeutic Potential for Organ Dysfunction Following Trauma or Sepsis. Stem Cells. 2017 Feb;35(2):316-324. doi: 10.1002/stem.2551. Epub 2017 Jan 19. PMID: 27888550.
  31. McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, Marshall J, Dos Santos C, Walley KR, Winston BW, Schlosser K, Fergusson DA; Canadian Critical Care Trials Group; Canadian Critical Care Translational Biology Group. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. Am J Respir Crit Care Med. 2018 Feb 1;197(3):337-347. doi: 10.1164/rccm.201705-1006OC. PMID: 28960096.
  32. Schlosser K, Wang JP, Dos Santos C, Walley KR, Marshall J, Fergusson DA, Winston BW, Granton J, Watpool I, Stewart DJ, McIntyre LA, Mei SHJ; Canadian Critical Care Trials Group and the Canadian Critical Care Translational Biology Group. Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients. Crit Care Med. 2019 Jul;47(7):918-925. doi: 10.1097/CCM.0000000000003657. PMID: 30720538; PMCID: PMC6629173.
  33. Alp E, Gonen ZB, Gundogan K, Esmaoglu A, Kaynar L, Cetin A, Karakukcu M, Cetin M, Kalin G, Doganay M. The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy. Emerg Med Int. 2022 Jun 24; 2022:9222379. doi: 10.1155/2022/9222379. PMID: 35784641; PMCID: PMC9249540.
  34. Blanco NG, Machado NM, Castro LL, Antunes MA, Takiya CM, Trugilho MRO, Silva LR, Paes Leme AF, Domingues RR, Pauletti BA, Miranda BT, Silva JD, Dos Santos CC, Silva PL, Rocco PRM, Cruz FF. Extracellular Vesicles from Different Sources of Mesenchymal Stromal Cells Have Distinct Effects on Lung and Distal Organs in Experimental Sepsis. Int J Mol Sci. 2023 May 4;24(9):8234. doi: 10.3390/ijms24098234. PMID: 37175936; PMCID: PMC10179270.
  35. Thanunchai M, Hongeng S, Thitithanyanont A. Mesenchymal Stromal Cells and Viral Infection. Stem Cells Int. 2015; 2015:860950. doi: 10.1155/2015/860950. Epub 2015 Jul 29. PMID: 26294919; PMCID: PMC4532961.
  36. Kallmeyer K, Ryder MA, Pepper MS. Mesenchymal Stromal Cells: A Possible Reservoir for HIV-1? Stem Cell Rev Rep. 2022 Apr;18(4):1253-1280. doi: 10.1007/s12015-021-10298-5. Epub 2022 Jan 1. PMID: 34973144; PMCID: PMC9033703.
  37. Kandula UR, Wake AD. Promising Stem Cell therapy in the Management of HIV and AIDS: A Narrative Review. Biologics. 2022 Jul 8; 16:89-105. doi: 10.2147/BTT.S368152. PMID: 35836496; PMCID: PMC9275675.
  38. Harrell CR, Popovska Jovicic B, Djonov V, Volarevic V. Molecular Mechanisms Responsible for Mesenchymal Stem Cell-Based Treatment of Viral Diseases. Pathogens. 2021 Apr 1;10(4):409. doi: 10.3390/pathogens10040409. PMID: 33915728; PMCID: PMC8066286.
  39. Brügger M, Démoulins T, Barut GT, Zumkehr B, Oliveira Esteves BI, Mehinagic K, Haas Q, Schögler A, Rameix-Welti MA, Eléouët JF, Moehrlen U, Marti TM, Schmid RA, Summerfield A, Posthaus H, Ruggli N, Hall SRR, Alves MP. Pulmonary mesenchymal stem cells are engaged in distinct steps of host response to respiratory syncytial virus infection. PLoS Pathog. 2021 Jul 28;17(7):e1009789. doi: 10.1371/journal.ppat.1009789. PMID: 34320038; PMCID: PMC8351988.
  40. Masterson CH, Ceccato A, Artigas A, Dos Santos C, Rocco PR, Rolandsson Enes S, Weiss DJ, McAuley D, Matthay MA, English K, Curley GF, Laffey JG. Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges. Intensive Care Med Exp. 2021 Dec 31;9(1):61. doi: 10.1186/s40635-021-00424-5. PMID: 34970706; PMCID: PMC8718182.
  41. Liao Y, Fu Z, Huang Y, Wu S, Wang Z, Ye S, Zeng W, Zeng G, Li D, Yang Y, Pei K, Yang J, Hu Z, Liang X, Hu J, Liu M, Jin J, Cai C. Interleukin-18-primed human umbilical cord-mesenchymal stem cells achieve superior therapeutic efficacy for severe viral pneumonia via enhancing T-cell immunosuppression. Cell Death Dis. 2023 Jan 28;14(1):66. doi: 10.1038/s41419-023-05597-3. PMID: 36707501; PMCID: PMC9883134.
  42. Chan MC, Kuok DI, Leung CY, Hui KP, Valkenburg SA, Lau EH, Nicholls JM, Fang X, Guan Y, Lee JW, Chan RW, Webster RG, Matthay MA, Peiris JS. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3621-6. doi: 10.1073/pnas.1601911113. Epub 2016 Mar 14. PMID: 26976597; PMCID: PMC4822574.
  43. Jankauskaite L, Schmoldt C, Lohmeyer J, Herold S. LSC Abstract: Murine bone marrow-derived mesenchymal stem cells exert antiviral and barrier-protective properties in influenza virus infection. Eur Respir J. 2015; 46: OA3515. doi: 10.1183/13993003.congress-2015.OA3515
  44. Klimova RR, Momotyuk ЕD, Demidova NA, Yarigina EI, Kushch AA. [Mesenchymal stem cells enhance immune response and protect mice against lethal herpes viral infection.]. Vopr Virusol. 2018;63(6):261-267. Russian. doi: 10.18821/0507-4088-2018-63-6-261-267. PMID: 30641021.
  45. Oh SJ, Lee EN, Park JH, Lee JK, Cho GJ, Park IH, Shin OS. Anti-Viral Activities of Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Against Human Respiratory Viruses. Front Cell Infect Microbiol. 2022 Apr 21; 12:850744. doi: 10.3389/fcimb.2022.850744. PMID: 35558099; PMCID: PMC9085650.
  46. Sleem A, Saleh F. Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy. Curr Res Transl Med. 2020 Aug;68(3):105-110. doi: 10.1016/j.retram.2020.04.003. Epub 2020 May 1. PMID: 32616467; PMCID: PMC7252154.
  47. Cheng F, Huang Z, Wei W, Li Z. Mesenchymal Stem Cell Transplantation For Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. Curr Stem Cell Res Ther. 2023;18(6):834-842. doi: 10.2174/1574888X18666221214123844. PMID: 36518036.
  48. Lin BL, Chen JF, Qiu WH, Wang KW, Xie DY, Chen XY, Liu QL, Peng L, Li JG, Mei YY, Weng WZ, Peng YW, Cao HJ, Xie JQ, Xie SB, Xiang AP, Gao ZL. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017 Jul;66(1):209-219. doi: 10.1002/hep.29189. Epub 2017 May 27. PMID: 28370357.
  49. Wang L, Zhang Z, Xu R, Wang X, Shu Z, Chen X, Wang S, Liu J, Li Y, Wang L, Zhang M, Yang W, Wang Y, Huang H, Tu B, Liang Z, Li L, Li J, Hou Y, Shi M, Wang FS. Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS: a multicenter randomized controlled trial. Signal Transduct Target Ther. 2021 Jun 9;6(1):217. doi: 10.1038/s41392-021-00607-2. PMID: 34103473; PMCID: PMC8187429.
  50. Trujillo-Rodríguez M, Viciana P, Rivas-Jeremías I, Álvarez-Ríos AI, Ruiz-García A, Espinosa-Ibáñez O, Arias-Santiago S, Martínez-Atienza J, Mata R, Fernández-López O, Ruiz-Mateos E, Gutiérrez-Valencia A, López-Cortés LF. Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial. Stem Cells Transl Med. 2021 Apr;10(4):534-541. doi: 10.1002/sctm.20-0213. Epub 2020 Dec 2. PMID: 33264515; PMCID: PMC7980217.
  51. Wang J, Shi P, Chen D, Wang S, Wang P, Feng X, Zhang L. Research Status of the Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of COVID-19-Related Pneumonia: A Systematic Review and Meta-Analysis. Stem Cells Dev. 2021 Oct 1;30(19):947-969. doi: 10.1089/scd.2021.0179. PMID: 34416823.
  52. Zhang Z, Shao S, Liu X, Tong Z. Effect and safety of mesenchymal stem cells for patients with COVID-19: Systematic review and meta-analysis with trial sequential analysis. J Med Virol. 2023 Apr;95(4):e28702. doi: 10.1002/jmv.28702. PMID: 36964933.
  53. Liu Q, Ma F, Zhong Y, Wang G, Hu L, Zhang Y, Xie J. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2023 May 4;14(1):118. doi: 10.1186/s13287-023-03286-8. PMID: 37143167; PMCID: PMC10159228.
  54. Taufiq H, Shaik Fakiruddin K, Muzaffar U, Lim MN, Rusli S, Kamaluddin NR, Esa E, Abdullah S. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19. Ther Adv Respir Dis. 2023 Jan-Dec; 17:17534666231158276. doi: 10.1177/17534666231158276. PMID: 37128999; PMCID: PMC10140776.
  55. Chen L, Xu Q, Sheng F, Wang B. Efficacy and Safety of Mesenchymal Stem Cells for COVID-19 Infection: A Meta-Analysis and Systematic Review. Discov Med. 2023 Apr 1;35(175):201-207. doi: 10.24976/Discov.Med.202335175.21. PMID: 37105930.
  56. Kirkham AM, Monaghan M, Bailey AJM, Shorr R, Lalu MM, Fergusson DA, Allan DS. Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19. Cytotherapy. 2022 Jun;24(6):639-649. doi: 10.1016/j.jcyt.2021.12.001. Epub 2022 Jan 31. PMID: 35219584; PMCID: PMC8802614.
  57. Yao W, Dong H, Qi J, Zhang Y, Shi L. Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2022 Jul 9;51:101545. doi: 10.1016/j.eclinm.2022.101545. PMID: 35844767; PMCID: PMC9270852.
  58. Javed A, Karki S, Sami Z, Khan Z, Shree A, Sah BK, Ghosh S, Saxena S. Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends. Biomed Res Int. 2022 Jun 22; 2022:9346939. doi: 10.1155/2022/9346939. PMID: 35782071; PMCID: PMC9242780.
  59. Cao JX, You J, Wu LH, Luo K, Wang ZX. Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review. World J Clin Cases. 2022 Sep 26;10(27):9714-9726. doi: 10.12998/wjcc.v10.i27.9714. PMID: 36186213; PMCID: PMC9516915.
  60. Nandina RQ, Eriani K, Asrizal CW, Azhar Al. Mesenchymal stem cell as a successful therapy for COVID-19 patient: Systematic review. Biosaintifica. 2022; 14 (1): 36-47. doi:15294/biosaintifika.v14i1. 32367
  61. Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells. 2020 Apr 9;9(4):924. doi: 10.3390/cells9040924. PMID: 32283815; PMCID: PMC7226831.
  62. Rogers CJ, Harman RJ, Bunnell BA, Schreiber MA, Xiang C, Wang FS, Santidrian AF, Minev BR. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. J Transl Med. 2020 May 18;18(1):203. doi: 10.1186/s12967-020-02380-2. PMID: 32423449; PMCID: PMC7232924.
  63. Liu S, Peng D, Qiu H, Yang K, Fu Z, Zou L. Mesenchymal stem cells as a potential therapy for COVID-19. Stem Cell Res Ther. 2020 May 4;11(1):169. doi: 10.1186/s13287-020-01678-8. PMID: 32366290; PMCID: PMC7197031.
  64. Zumla A, Wang FS, Ippolito G, Petrosillo N, Agrati C, Azhar EI, Chang C, El-Kafrawy SA, Osman M, Zitvogel L, Galle PR, Locatelli F, Gorman E, Cordon-Cardo C, O'Kane C, McAuley D, Maeurer M. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis. 2020 Jul; 96:431-439. doi: 10.1016/j.ijid.2020.05.040. Epub 2020 May 17. PMID: 32425638; PMCID: PMC7231497.
  65. Rajarshi K, Chatterjee A, Ray S. Combating COVID-19 with mesenchymal stem cell therapy. Biotechnol Rep (Amst). 2020 May 14;26:e00467. doi: 10.1016/j.btre.2020.e00467. PMID: 32420049; PMCID: PMC7224671.
  66. Li TT, Zhang B, Fang H, Shi M, Yao WQ, Li Y, Zhang C, Song J, Huang L, Xu Z, Yuan X, Fu JL, Zhen C, Zhang Y, Wang ZR, Zhang ZY, Yuan MQ, Dong T, Bai R, Zhao L, Cai J, Dong J, Zhang J, Xie WF, Li Y, Shi L, Wang FS. Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2023 Jun; 92:104600. doi: 10.1016/j.ebiom.2023.104600. Epub 2023 May 5. PMID: 37149930; PMCID: PMC10161678.
  67. Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, Song J, Huang L, Xu Z, Fu JL, Li Y, Xu R, Li TT, Dong J, Cai J, Li G, Xie Y, Shi M, Li Y, Zhang Y, Xie WF, Wang FS. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2022 Jan; 75:103789. doi: 10.1016/j.ebiom.2021.103789. Epub 2021 Dec 25. PMID: 34963099; PMCID: PMC8709782.
  68. Rebelatto CLK, Senegaglia AC, Franck CL, Daga DR, Shigunov P, Stimamiglio MA, Marsaro DB, Schaidt B, Micosky A, de Azambuja AP, Leitão CA, Petterle RR, Jamur VR, Vaz IM, Mallmann AP, Carraro Junior H, Ditzel E, Brofman PRS, Correa A. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther. 2022 Mar 21;13(1):122. doi: 10.1186/s13287-022-02796-1. PMID: 35313959; PMCID: PMC8935270.
  69. Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Richeldi L, Corsico AG. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? Cells. 2021 May 14;10(5):1203. doi: 10.3390/cells10051203. PMID: 34068958; PMCID: PMC8155949.
  70. Devi A, Pahuja I, Singh SP, Verma A, Bhattacharya D, Bhaskar A, Dwivedi VP, Das G. Revisiting the role of mesenchymal stem cells in tuberculosis and other infectious diseases. Cell Mol Immunol. 2023 Jun;20(6):600-612. doi: 10.1038/s41423-023-01028-7. Epub 2023 May 12. PMID: 37173422; PMCID: PMC10176304.
  71. Zhang X, Xie Q, Ye Z, Li Y, Che Z, Huang M, Zeng J. Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities. Front Immunol. 2021 Jul 22; 12:695278. doi: 10.3389/fimmu.2021.695278. PMID: 34367155; PMCID: PMC8340780.
  72. Jain N, Kalam H, Singh L, Sharma V, Kedia S, Das P, Ahuja V, Kumar D. Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis. Nat Commun. 2020 Jun 16;11(1):3062. doi: 10.1038/s41467-020-16877-3. PMID: 32546788; PMCID: PMC7297998.
  73. Khan A, Hunter RL, Jagannath C. Emerging role of mesenchymal stem cells during tuberculosis: The fifth element in cell mediated immunity. Tuberculosis (Edinb). 2016 Dec; 101S:S45-S52. doi: 10.1016/j.tube.2016.09.019. Epub 2016 Sep 28. PMID: 27743705.
  74. Pathak L, Das B. Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the Secret Role of Bone Marrow Derived Stem Cells. Front Immunol. 2021 Jan 21; 11:594572. doi: 10.3389/fimmu.2020.594572. PMID: 33584661; PMCID: PMC7873989.
  75. Raghuvanshi S, Sharma P, Singh S, Van Kaer L, Das G. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21653-8. doi: 10.1073/pnas.1007967107. Epub 2010 Dec 6. PMID: 21135221; PMCID: PMC3003090.
  76. Liu M, Wang Z, Ren S, Zhao H. Exosomes derived from mycobacterium tuberculosis-infected MSCs induce a pro-inflammatory response of macrophages. Aging (Albany NY). 2021 Apr 19;13(8):11595-11609. doi: 10.18632/aging.202854. Epub 2021 Apr 19. PMID: 33872217; PMCID: PMC8109131.
  77. Erokhin VV, Vasil'eva IA, Konopliannikov AG, Chukanov VI, Tsyb AF, Bagdasarian TR, Danilenko AA, Lepekhina LA, Kal'sina SSh, Semenkova IV, Agaeva EV. [Systemic transplantation of autologous mesenchymal stem cells of the bone marrow in the treatment of patients with multidrug-resistant pulmonary tuberculosis]. Probl Tuberk Bolezn Legk. 2008;(10):3-6. Russian. PMID: 19086127.
  78. Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y, Skrahina A, Zumla A, Maeurer MJ. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med. 2014 Feb;2(2):108-22. doi: 10.1016/S2213-2600(13)70234-0. Epub 2014 Jan 9. PMID: 24503266.
  79. Skrahin AE, Jenkins HE, Hurevich H, Solodovnokova V, Isaikina Y, Klimuk D, Rohava Z, Skrahina A. Potential role of autologous mesenchymal stromal cells in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J. 2016; 48: PA1919. doi: 10.1183/13993003. congress-2016.PA1919
  80. Elsawey AM, Etewa SE, Aboulfotouh N. Stem cell therapy research for the treatment of parasitic infections. Parasitol United J. 2022; 15 (3): 232-237. doi: 10.21608/puj.2022.156355.1185
  81. Aryamand S, Khademvatan S, Diba K, Manafpour N, Abbasi E. Stem cell therapy in the treatment of parasitic diseases. Iran J Med Microbiol. 2017; 11 (3): 01-09.
  82. Wang W, Qian H, Cao J. Stem cell therapy: a novel treatment option for cerebral malaria? Stem Cell Res Ther. 2015 Aug 8;6(1):141. doi: 10.1186/s13287-015-0138-6. PMID: 26253514; PMCID: PMC4529732.
  83. Lima MN, Oliveira HA, Fagundes PM, Estato V, Silva AYO, Freitas RJRX, Passos BABR, Oliveira KS, Batista CN, Vallochi AL, Rocco PRM, Castro-Faria-Neto HC, Maron-Gutierrez T. Mesenchymal stromal cells protect against vascular damage and depression-like behavior in mice surviving cerebral malaria. Stem Cell Res Ther. 2020 Aug 26;11(1):367. doi: 10.1186/s13287-020-01874-6. PMID: 32843073; PMCID: PMC7448996.
  84. de Carvalho KA, Abdelwahid E, Ferreira RJ, Irioda AC, Guarita-Souza LC. Preclinical stem cell therapy in Chagas Disease: Perspectives for future research. World J Transplant. 2013 Dec 24;3(4):119-26. doi: 10.5500/wjt.v3.i4.119. PMID: 24392316; PMCID: PMC3879521.
  85. Guarita-Souza LC, Carvalho KA, Woitowicz V, Rebelatto C, Senegaglia A, Hansen P, Miyague N, Francisco JC, Olandoski M, Faria-Neto JR, Brofman P. Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation. 2006 Jul 4;114(1 Suppl):I120-4. doi: 10.1161/CIRCULATIONAHA.105.000646. PMID: 16820560.
  86. Silva DN, de Freitas Souza BS, Azevedo CM, Vasconcelos JF, Carvalho RH, Soares MB, Dos Santos RR. Intramyocardial transplantation of cardiac mesenchymal stem cells reduces myocarditis in a model of chronic Chagas disease cardiomyopathy. Stem Cell Res Ther. 2014 Jul 1;5(4):81. doi: 10.1186/scrt470. PMID: 24984860; PMCID: PMC4229984.

 

  1. Silva DN, Souza BSF, Vasconcelos JF, Azevedo CM, Valim CXR, Paredes BD, Rocha VPC, Carvalho GB, Daltro PS, Macambira SG, Nonaka CKV, Ribeiro-Dos-Santos R, Soares MBP. Granulocyte-Colony Stimulating Factor-Overexpressing Mesenchymal Stem Cells Exhibit Enhanced Immunomodulatory Actions Through the Recruitment of Suppressor Cells in Experimental Chagas Disease Cardiomyopathy. Front Immunol. 2018 Jun 25; 9:1449. doi: 10.3389/fimmu.2018.01449. PMID: 30013550; PMCID: PMC6036245.
  2. Zheng G, Huang R, Qiu G, Ge M, Wang J, Shu Q, Xu J. Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis. Cell Tissue Res. 2018 Oct;374(1):1-15. doi: 10.1007/s00441-018-2871-5. Epub 2018 Jun 28. PMID: 29955951.
  3. Cheng Y, Cao X, Qin L. Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Novel Cell-Free Therapy for Sepsis. Front Immunol. 2020 Apr 21; 11:647. doi: 10.3389/fimmu.2020.00647. PMID: 32373121; PMCID: PMC7186296.
  4. Manzoor T, Saleem A, Farooq N, Dar LA, Nazir J, Saleem S, Ismail S, Gugjoo MB, Shiekh PA, Ahmad SM. Extracellular vesicles derived from mesenchymal stem cells - a novel therapeutic tool in infectious diseases. Inflamm Regen. 2023 Feb 28;43(1):17. doi: 10.1186/s41232-023-00266-6. PMID: 36849892; PMCID: PMC9970864.
  5. You J, Fu Z, Zou L. Mechanism and Potential of Extracellular Vesicles Derived from Mesenchymal Stem Cells for the Treatment of Infectious Diseases. Front Microbiol. 2021 Oct 26; 12:761338. doi: 10.3389/fmicb.2021.761338. PMID: 34764947; PMCID: PMC8576143.
  6. Yousefi Dehbidi M, Goodarzi N, Azhdari MH, Doroudian M. Mesenchymal stem cells and their derived exosomes to combat Covid-19. Rev Med Virol. 2022 Mar;32(2):e2281. doi: 10.1002/rmv.2281. Epub 2021 Aug 7. PMID: 34363275; PMCID: PMC8420536.
  7. Akbari A, Rezaie J. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia. Stem Cell Res Ther. 2020 Aug 14;11(1):356. doi: 10.1186/s13287-020-01866-6. PMID: 32795359; PMCID: PMC7427273.
  8. Chu M, Wang H, Bian L, Huang J, Wu D, Zhang R, Fei F, Chen Y, Xia J. Nebulization Therapy with Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for COVID-19 Pneumonia. Stem Cell Rev Rep. 2022 Aug;18(6):2152-2163. doi: 10.1007/s12015-022-10398-w. Epub 2022 Jun 4. PMID: 35665467; PMCID: PMC9166932.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?